ESR1 and breast carcinoma: To sum up, NET does not offer any clear advantages in terms of clinical response or BCS rates when compared to NCT, but it definitely implies less toxicity and better tolerance, thus constituting a safe and effective option for ER+ breast cancers [17,18].